Last mentioned: Mar 10, 2026
Potential Approval
Estimated decision date if the FDA grants a 6-month priority review.
Potential Approval
Estimated approval date based on 6-month priority review timeline.
FDA Filing Deadline
Target date for completing the accelerated approval application with the FDA.
FDA Filing Deadline
Target date for completing the BLA application for accelerated approval.
Phase 3 Success
Vertex reports povetacicept met primary goals in late-stage IgA nephropathy trial.
Phase 3 Success
Vertex announces povetacicept met primary endpoint in IgA nephropathy trial.
Alpine Acquisition
Vertex announces $4.9 billion acquisition of Alpine Immune Sciences to gain povetacicept.
Alpine Acquisition
Vertex acquires Alpine Immune Sciences for $4.9B to obtain povetacicept.
Vertex Pharmaceuticals reported that its Phase 3 trial for povetacicept met its primary endpoint, showing a 52% reduction in proteinuria for patients with IgA nephropathy. The company plans to file for FDA accelerated approval by the end of March 2026, utilizing a priority review voucher to expedite the process.
Vertex Pharmaceuticals reported that its lead kidney drug candidate, povetacicept, achieved a 52% reduction in proteinuria in a late-stage trial for IgA nephropathy. The success validates Vertex's $4.9 billion acquisition of Alpine Immune Sciences and marks a significant step in its strategy to diversify beyond cystic fibrosis.